Table 3.
Cox regression analysis of relative risks of death within 5 years according to EGFR and PODXL expression in colorectal cancer
| Cohort 1 | Cohort 2 | Cohort 3 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| HR (95 % CI) | HR (95 % CI) | N (events) | HR (95 % CI) | HR (95 % CI) | N (events) | HR (95 % CI) | HR (95 % CI) | N (events) | |
| Unadjusted | Adjusted | Unadjusted | Adjusted | Unadjusted | Adjusted | ||||
| All | |||||||||
| EGFR low | 1.00 | 1.00 | 419 (146) | 1.00 | 1.00 | 202 (101) | 1.00 | 1.00 | 259 (88) |
| EGFR high | 1.82 (1.35–2.46) | 1.77 (1.27–2.46) | 114 (61) | 1.98 (1.39–2.84) | 1.58 (1.05–2.38) | 57 (43) | 2.60 (1.74–3.89) | 1.83 (1.19–2.81) | 51 (33) |
| All | |||||||||
| PODXL low | 1.00 | 1.00 | 464 (168) | 1.00 | 1.00 | 235 (123) | 1.00 | 1.00 | 291 (103) |
| PODXL high | 1.73 (1.21–2.46) | 1.16 (0.77–1.73) | 72 (38) | 2.27 (1.43–3.62) | 1.91 (1.11–3.27) | 25 (21) | 3.45 (2.13–5.58) | 1.23 (0.68–2.22) | 25 (20) |
| EGFR low | |||||||||
| PODXL low | 1.00 | 1.00 | 373 (128) | 1.00 | 1.00 | 183 (89) | 1.00 | 1.00 | 247 (82) |
| PODXL high | 1.06 (0.58–1.91) | 0.87 (0.45–1.66) | 34 (12) | 2.02 (1.02–4.02) | 2.59 (1.26–5.31) | 12 (9) | 1.62 (0.65–3.99) | 0.74 (0.28–1.95) | 10 (5) |
| EGFR high | |||||||||
| PODXL low | 1.00 | 1.00 | 75 (35) | 1.00 | 1.00 | 44 (31) | 1.00 | 1.00 | 37 (19) |
| PODXL high | 1.97 (1.18–3.28) | 1.38 (0.71–2.68) | 37 (26) | 1.60 (0.80–3.21) | 1.69 (0.74–3.84) | 12 (11) | 3.56 (1.75–7.22) | 3.71 (1.23–11.20) | 14 (14) |
Cohort 1 and 2 adjusted for age at surgery, sex, PODXL, EGFR, T-, N-, M-stage, differentiation grade and vascular invasion in multivariable analysis
Cohort 3 adjusted for age at surgery, sex, PODXL, EGFR, T-, N-, M-stage, differentiation grade, vascular invasion and neural invasion in multivariable analysis